Cutaneous T-Cell Lymphoma: Types, Symptoms, Causes & Treatment


Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. It originates from T lymphocytes, a type of white blood cell that plays a central role in the body’s immune response. CTCL is characterized by the abnormal proliferation of malignant T cells in the skin, leading to the development of various skin lesions and other symptoms.

Types of Cutaneous T-Cell Lymphoma:

  1. Mycosis Fungoides (MF): Mycosis fungoides is the most common type of CTCL. It typically presents as patches, plaques, or tumors on the skin. In the early stages, the lesions may resemble eczema or psoriasis, making diagnosis challenging.
  2. Sézary Syndrome: Sézary syndrome is a more aggressive form of CTCL characterized by the presence of malignant T cells circulating in the blood, known as Sézary cells. Patients with Sézary syndrome often experience widespread erythroderma (redness of the skin) and may develop lymphadenopathy (enlarged lymph nodes) and systemic symptoms.
  3. Primary Cutaneous CD30+ Lymphoproliferative Disorders: This group includes several rare CTCL subtypes characterized by the expression of CD30 antigen on malignant T cells. Examples include lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.

Symptoms and Diagnosis:

The symptoms of CTCL can vary depending on the subtype and stage of the disease. Common symptoms include:

  • Red, scaly patches or plaques on the skin
  • Itching (pruritus)
  • Thickened or raised lesions
  • Ulceration or bleeding of skin lesions
  • Enlarged lymph nodes
  • Systemic symptoms such as fever, weight loss, and fatigue (in advanced stages)

Diagnosing CTCL often involves a combination of clinical evaluation, skin biopsy, and molecular testing. A dermatologist or hematologist/oncologist may perform a skin biopsy to examine skin lesions under a microscope and assess the presence of abnormal T cells. Additional tests such as blood tests, imaging studies (e.g., CT scans), and flow cytometry may be conducted to determine the extent of the disease.

Treatment Options:

The management of CTCL depends on several factors, including the subtype, stage, and overall health of the patient. Treatment options may include:

  1. Topical Therapies: Corticosteroids, topical chemotherapy, and retinoids may be prescribed for early-stage CTCL lesions confined to the skin.
  2. Phototherapy: Light-based therapies such as PUVA (psoralen plus ultraviolet A) or narrowband UVB phototherapy can be effective in treating skin lesions.
  3. Systemic Therapies: For more advanced or refractory cases, systemic treatments such as oral retinoids, interferon, chemotherapy, targeted therapies, and immunomodulatory agents may be recommended.
  4. Biological Therapies: Monoclonal antibodies targeting specific molecules on malignant T cells, such as mogamulizumab, may be used in certain cases.
  5. Stem Cell Transplantation: In rare cases of aggressive or refractory CTCL, high-dose chemotherapy followed by autologous stem cell transplantation may be considered.


The prognosis of CTCL varies widely depending on the subtype, stage, and response to treatment. While early-stage CTCL often has a favorable prognosis with long-term survival, advanced-stage disease may be associated with a poorer prognosis and shorter survival. Regular follow-up appointments with a multidisciplinary team of dermatologists, oncologists, and other specialists are essential for monitoring disease progression and adjusting treatment as needed.

In conclusion, cutaneous T-cell lymphoma is a rare type of lymphoma that primarily affects the skin. Early diagnosis and appropriate management are crucial for optimizing outcomes and improving quality of life for patients with CTCL. Ongoing research into the underlying biology of CTCL and the development of novel treatment strategies hold promise for advancing the care and prognosis of individuals affected by this challenging disease.


Most read